Opinion

Video

Impact of Rectal Spacers on Sexual Quality-of-Life After Radiotherapy in Patients With Prostate Cancer

Author(s):

Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO

Analysis of SpaceOAR trial and pooled data found reduced penile bulb radiation dose correlated with better preservation of sexual function over long-term follow-up, suggesting rectal spacers help maintain erectile function in some men with prostate cancer undergoing radiation therapy.

Current Time 
Duration 
Loaded: 0%
Stream Type LIVE
Remaining Time 
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected
      Related Videos
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
      Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
      1 expert in this video
      Selecting Between Receptor Pathway Inhibitors for mHSPC
      1 expert in this video
      The Use of Ultra-Low PSA in Specific Patient Profiles
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
      Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
      Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
      Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
      Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
      Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
      1 expert in this video
      Using Ultrasensitive PSA Assays in Routine Practice
      1 expert in this video
      Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
      Related Content
      AI-based tool aims to optimize MRI use in prostate cancer diagnosis
      June 12th 2025

      AI-based tool aims to optimize MRI use in prostate cancer diagnosis

      Madhur Nayan, MD, PhD
      "I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
      June 9th 2025

      Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

      Hannah Clarke
      In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Amy L. Shaver, PhD, PharmD, MPH
      June 5th 2025

      GLP-1 agonist use is rising in men with prostate cancer

      Benjamin P. Saylor
      In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
      Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
      June 4th 2025

      ARANOTE: Darolutamide improves HRQoL in mHSPC

      Benjamin P. Saylor
      Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
      © 2025 MJH Life Sciences

      All rights reserved.